Pro-Forma Q1 2019 Revenue including 180 Smoke for a full quarter would have been $13.1 million
OTTAWA , May 29, 2019 /CNW/ - CannaRoyalty Corp. d/b/a Origin House (OH.CN) (ORHOF) ("Origin House" or the "Company"), a North American cannabis products and brands company, today announced its financial results for the three months ended March 31, 2019 . All figures are reported in Canadian dollars ($), unless otherwise indicated. Origin House's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").
As previously announced, the Company will hold a Special Meeting of shareholders on June 11, 2019 in connection with its previously announced statutory plan of arrangement pursuant to which Cresco Labs Inc. ("Cresco Labs") will acquire all of the issued and outstanding shares of Origin House (the "Arrangement").
Marc Lustig , CEO and Chairman of Origin House commented, "This was a milestone quarter for Origin House, as the team drove solid organic growth within our Californian distribution and brands platform and completed meaningful strategic merger and acquisition-based initiatives including the addition of 180 Smoke in Canada . Moving forward through the balance of the year, we are confident that, once completed, the combination of Cresco Labs' scale and Origin House's California -wide distribution footprint will further accelerate growth and build significant value for the shareholders of both companies."
Financial Highlights for the first quarter ended March 31, 2019
The following are financial highlights of Origin House's operating results for the three months ended March 31, 2019 , compared to the three months ended March 31, 2018 :
The following is a summary of key balance sheet items as at March 31, 2019 , compared to December 31 , 2018:
Pro-Forma Disclosure
If the 180 Smoke acquisition had occurred on January 1, 2019 , management estimates that for the three months ended March 31 , 2019:
Corporate Highlights subsequent to the quarter ended March 31, 2019
For a more comprehensive overview of these recent developments, please refer to Origin House's Management Discussion and Analysis of the Financial Condition and Results of Operations for the Three Months ended March 31, 2019 .
Results of Operations
(Summary)
The following tables set forth consolidated statements of financial information for the three months ended March 31, 2019 and March 31, 2018 . For further information regarding the Company's financial results for these periods, please refer to the Company's Management's Discussion and Analysis for the periods ended March 31, 2019 and March 31, 2018 and the Company's Financial Statements for the periods ended March 31, 2019 and March 31, 2018 , published on Origin House's issuer profile on SEDAR at www.sedar.com and the Company's website at www.OriginHouse.com.
March 31 |
December 31 |
Change |
||||
Selected statement of financial position data |
||||||
Cash and cash equivalents |
$ |
39,252,543 |
$ |
69,206,193 |
$ |
(29,953,650) |
Working capital |
34,424,203 |
59,810,772 |
(25,386,569) |
|||
Total investments (1) |
20,581,294 |
21,741,531 |
(1,160,237) |
|||
Total assets |
269,412,325 |
230,698,045 |
38,714,280 |
|||
Long term and convertible debt |
- |
16,026,098 |
(16,026,098) |
|||
Shareholders' equity |
199,588,739 |
172,972,132 |
26,616,607 |
|||
Dividend per share |
- |
- |
- |
|||
(1) This represents the sum of investments, royalty investments, and interests in equity method investees |
Three months ended March 31 |
|||||
2019 |
2018 |
% change |
|||
Consolidated statements of comprehensive loss |
|||||
Revenue |
$ |
11,161,161 |
$ |
643,437 |
1635% |
Gross margin, excluding fair value items |
1,516,775 |
(29,630) |
5219% |
||
Gross margin, including fair value items |
1,652,727 |
(29,630) |
5678% |
||
Operating expenses |
18,230,434 |
4,480,014 |
307% |
||
Loss from operations |
(16,577,707) |
(4,509,644) |
268% |
||
Net loss |
(17,434,280) |
(4,654,473) |
275% |
||
Other comprehensive loss |
(3,047,605) |
545,605 |
(659%) |
||
Total comprehensive loss |
(20,481,885) |
(4,108,868) |
398% |
||
Net loss attributable to owners of the Company |
(17,136,306) |
(4,629,003) |
270% |
||
Net loss per common share - basic & diluted |
(0.25) |
(0.10) |
150% |
||
Weighted average common shares - basic & diluted |
68,579,886 |
45,075,695 |
52% |
Revenue by Type
Three months ended March 31 |
% change |
||||
2019 |
2018 |
||||
California Operations segment |
|||||
Product sales |
$ |
9,247,507 |
$ |
84,773 |
10809% |
Interest income |
23,628 |
- |
|||
Other Income |
30,806 |
- |
|||
Canadian Operations segment |
|||||
Product sales |
1,554,015 |
- |
|||
Royalties |
11,266 |
- |
|||
Corporate segment |
|||||
Services |
33,807 |
429,817 |
(92%) |
||
Royalties |
- |
119,058 |
(100%) |
||
Interest income |
260,132 |
9,789 |
2557% |
||
Total |
$ |
11,161,161 |
$ |
643,437 |
1635% |
Cost of Sales by Revenue Type
Three months ended March 31 |
% change |
||||
2019 |
2018 |
||||
California Operations segment |
|||||
Cost of product sales |
$ |
8,767,894 |
$ |
75,673 |
11487% |
Canadian Operations segment |
|||||
Cost of product sales |
850,709 |
- |
|||
Corporate segment |
|||||
Cost of services |
8,745 |
209,023 |
(96%) |
||
Cost of royalties |
17,038 |
388,371 |
(96%) |
||
Total |
$ |
9,644,386 |
$ |
673,067 |
1333% |
Gross Profit by Revenue Type
Three months ended March 31 |
% change |
||||
2019 |
2018 |
||||
California Operations segment |
|||||
Products |
$ |
479,613 |
$ |
9,100 |
5170% |
Interest income |
23,628 |
- |
|||
Other Income |
30,806 |
- |
|||
Canadian Operations segment |
|||||
Products |
703,306 |
- |
|||
Royalties |
11,266 |
- |
|||
Corporate segment |
|||||
Services |
25,062 |
220,794 |
(89%) |
||
Royalties |
(17,038) |
(269,313) |
94% |
||
Interest |
260,132 |
9,789 |
2557% |
||
Gross margin, excluding fair value items |
$ |
1,516,775 |
$ |
(29,630) |
5219% |
Realized fair value amounts of inventory sold |
(971,143) |
- |
|||
Unrealized fair value gain on biological assets |
1,107,095 |
- |
|||
Gross margin |
$ |
1,652,727 |
$ |
(29,630) |
5678% |
Gross Margin by Revenue Type
Three months ended March 31 |
% change |
||
2019 |
2018 |
||
California Operations segment |
|||
Products |
5% |
11% |
52% |
Interest income |
100% |
- |
|
Other Income |
100% |
- |
|
Canadian Operations segment |
|||
Products |
45% |
- |
|
Royalties |
100% |
- |
|
Corporate segment |
|||
Services |
74% |
51% |
44% |
Royalties |
- |
(226%) |
(100%) |
Interest |
100% |
100% |
- |
Gross margin, excluding fair value items |
14% |
(5%) |
(395%) |
Effect of changes in fair value of biological assets on margin |
1% |
- |
|
Gross margin |
15% |
(5%) |
(422%) |
Operating Expenses
Three months ended March 31 |
|||||
2019 |
2018 |
Change |
|||
Sales and marketing |
$ |
4,444,982 |
$ |
478,516 |
829% |
Research and product development |
786,225 |
75,965 |
935% |
||
General and administrative |
11,356,889 |
3,750,426 |
203% |
||
Amortization of intangibles |
1,642,338 |
175,107 |
838% |
||
Total |
$ |
18,230,434 |
$ |
4,480,014 |
307% |
Non-IFRS Financial Measures
The
Company has provided unaudited pro forma financial information,
which assumes that closed mergers and acquisitions in 2019 are
included in the Company's financial results as of the beginning of
fiscal 2019. EBITDA and Adjusted EBITDA are non-IFRS measures and
do not have standardized definitions under IFRS. The Company has
provided the non-IFRS financial measures, which are not calculated
or presented in accordance with IFRS, as supplemental information
and in addition to the financial measures that are calculated and
presented in accordance with IFRS. These supplemental non-IFRS
financial measures are presented because management has evaluated
the financial results both including and excluding the adjusted
items and believe that the supplemental non-IFRS financial measures
presented provide additional perspective and insights when
analyzing the core operating performance of the business.